EMA Validates Type II Variation Application for PADCEV (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for 1L Treatment of Advanced Bladder Cancer
Ahsan Arozullah, M.D., M.P.H., Senior Vice President, Head of Oncology Development, Astellas commented, “Patients in Europe need better treatment options for advanced stage urothelial cancer, and we look forward to working with the EMA on their review of the combination of enfortumab vedotin and pembrolizumab. If approved, the combination would be the first alternative to a chemotherapy-based treatment for this patient population. This milestone is another opportunity to affirm our commitment to helping patients with advanced urothelial cancer live longer.”
Share:
More News
Byoung-Chul Cho, MD, the CEO of DAAN Biotherapeutics, stated, “We will continue to innovate our technologies to develop cancer treatments that will change the lives of patients.”
“We are thrilled to have successfully locked down our TCR-NK cell therapy manufacturing process,” said Namir Hassan, CEO of Zelluna. “This pivotal achievement not only demonstrates our capability to produce high-quality, scalable TCR-NK cell therapies, but also underscores our commitment to advancing next-generation immunotherapies that could transform the treatment of
“We are very pleased that Sanofi has chosen to further strengthen our relationship through a potential strategic equity investment in the company. This would further validate the innovation and scientific progress at Innate Pharma delivered by our research and development. We acknowledge Sanofi’s portfolio prioritization, and we are encouraged to
